Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations

Background: The loop diuretic drug furosemide is widely used for the treatment of edema in various conditions, such as pulmonary, cardiac and hepatic edema, as well as cardiac infarction. Furosemide, due to its poor water solubility and low bioavailability after oral administration of conventional dosage form, is categorized as class IV in the biopharmaceutical classification system. Objective: In the case of furosemide, this release profile is responsible for various physiological problems, acute diuresis being the most serious. This adverse effect can be circumvented by the modified release of furosemide from tablet formulations compared to those forms designed for immediate release. Method: In this report, a D-optimal combined experimental design was applied for the development of furosemide containing bilayer and compression coated tablets, aiming at lowering the drug’s burst release in the acidic environment of the stomach. A D-optimal combined design was selected in order to include all requirements in one design with many levels for the factors examined. The following responses were selected as the ones reflecting better criteria for the desired drug release: dissolution at 120 min (30-40%), 300 min (60-70%) and 480 min >95%. The new formulations, suggested by the Doptimal combined design, incorporated different grades of Eudragit ® polymers (Eudragit® E100 and Eudragit® L100-55), lactose monohydrate and HPMC K15M. The dissolution profile of furosemide from these systems was probed via in vitro dissolution experiments in buffer solutions simulating the pH of the gastrointestinal tract. Results: The results indicate that the use of Eudragit® E100 in conjunction with lactose monohydrate led to 21.32-40.85 % drug release, in the gastric medium, in both compression-coated and bilayer tablets. This is lower than the release of the mainstream drug Lasix® (t=120 min, 44.5% drug release), implying longer gastric retention and drug waste minimization. Conclusion: Furosemide’s release in the intestinal environment, from compression coated tablets incorporating Eudragit® L100-55 and HPMC K15M in the inner core or one of the two layers of the bilayer tablets, was delayed, compared to Lasix®

Designs of Experiments for Beginners—A Quick Start Guide for Application to Electrode Formulation

In this paper, we will describe in detail the setting up of a Design of Experiments (DoE) applied to the formulation of electrodes for Li-ion batteries. We will show that, with software guidance, Designs of Experiments are simple yet extremely useful statistical tools to set up and embrace. An Optimal Combined Design was used to identify influential factors and pinpoint the optimal formulation, according to the projected use. Our methodology follows an eight-step workflow adapted from the literature. Once the study objectives are clearly identified, it is necessary to consider the time, cost, and complexity of an experiment before choosing the responses that best describe the system, as well as the factors to vary. By strategically selecting the mixtures to be characterized, it is possible to minimize the number of experiments, and obtain a statistically relevant empirical equation which links responses and design factors.